The GErman Italian Spanish Takotsubo (GEIST) Registry

Takotsubo Syndrome Clinical Trial

— GEIST  

Official title:

The GErman Italian Spanish Takotsubo (GEIST) Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04361994
• Other study ID #: 00
• Status: Recruiting
• Start date: April 2015
• Est. completion date: January 2025

Study information

• Verified date: May 2024
• Source: University of Luebeck
• Contact: Ingo Eitel, Prof. Dr.
• Phone: 004945150044501
• Email: ingo.eitel[@]uksh.de
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

GEIST is a multicenter, international observational registry of patients with Takotsubo syndrome. Data regarding the clinical profile (demographic characteristics, clinical presentation, laboratory measures, electrocardiography /echocardiography / coronary angiography parameters, treatment and medication), in-hospital course and complications and short-/long-term outcome are collected prospectively and retrospectively to increase the understanding of the disease.

Description:

The open-ended, multicenter, international GEIST registry collects data from patients with Takotsubo syndrome during the index hospitalization and follow-up. Furthermore, long-term outcome data are acquired with structured telephone interviews, in case patients do not undergo regular outpatient visits in the participating study centers. The GEIST registry retrospectively includes data, which have already been collected, and prospectively continues to enroll patients with newly diagnosed Takotsubo syndrome.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: January 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with Takotsubo syndrome

Exclusion Criteria:

• Non

Related Conditions & MeSH terms

• Takotsubo Cardiomyopathy
• Takotsubo Syndrome

Locations

Country	Name	City	State
Germany	Universität zu Lübeck	Lübeck	Schleswig-Holstein
Italy	University of Foggia	Foggia

Sponsors (2)

Lead Sponsor	Collaborator
Prof. Dr. med. Ingo Eitel	University of Foggia

Countries where clinical trial is conducted

Germany,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause mortality	All-cause mortality (in-hospital, short-term, long-term)	Day 0
Primary	All-cause mortality	All-cause mortality (in-hospital, short-term, long-term)	3 Month
Primary	All-cause mortality	All-cause mortality (in-hospital, short-term, long-term)	6 Month
Secondary	In-Hospital complications	Cardiogenic shock, pulmonary edema, death, life-threatening arrhythmias, ventricular thrombus formation, right ventricular involvement	Day 0